<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415350</url>
  </required_header>
  <id_info>
    <org_study_id>BAT-2006-MCA1</org_study_id>
    <secondary_id>BAT-2006</secondary_id>
    <nct_id>NCT00415350</nct_id>
  </id_info>
  <brief_title>Bronchiectasis and Long Term Azithromycin Treatment</brief_title>
  <acronym>BAT</acronym>
  <official_title>Bronchiectasis and Long Term Azithromycin Treatment: A Randomised Placebo-controlled Trial Studying Disease Modifying Effects of Immunomodulating Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.G.Boersma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Center Alkmaar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. SUMMARY&#xD;
&#xD;
      Rationale: Patients with bronchiectasis often experience lower respiratory tract infections&#xD;
      with progression of symptoms and decline in quality of life. Macrolides, as has been shown in&#xD;
      panbronchiolitis and cystic fibrosis, may break or weaken the link between infection and&#xD;
      inflammation resulting in an improvement of symptoms. Also the number of exacerbations may&#xD;
      lowered.&#xD;
&#xD;
      Objective: A reduction in number of infective exacerbations and improvement in lung function&#xD;
      by AZT treatment are the primary objectives. Secondary objectives that will be evaluated are:&#xD;
      symptoms score, quality of life, inflammatory parameters, bacterial colonisation, and adverse&#xD;
      events.&#xD;
&#xD;
      Study design: Randomised double blind multicenter study in the Netherlands. Patients will be&#xD;
      stratified for colonisation with P.aeruginosa.&#xD;
&#xD;
      Study population: Patients with bronchiectasis demonstrated by high-resolution computed&#xD;
      tomography (HR-CT) scan or bronchography.&#xD;
&#xD;
      Intervention: Patients receive Azithromycin 250mg(p.o.) once daily or placebo.&#xD;
&#xD;
      Main study parameters/endpoints: Reduction in number exacerbations, defined as increase&#xD;
      symptoms such as dyspnoea, coughing, and sputum production for which a course of prednisolone&#xD;
      and/or antibiotic is needed. Change in lung function parameters (forced expiratory volume in&#xD;
      1 second [FEV1], forced vital capacity [FVC]) measured by spirometry is the other primary&#xD;
      endpoint.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: The risk of participating in this study is low. Laboratory, radiographic&#xD;
      examinations, and pulmonary function tests are commonly used as diagnostic procedures during&#xD;
      outpatients visits and during exacerbations. Adverse effects in maintenance treatment with&#xD;
      AZT are usually mild and mainly gastrointestinal. Sometimes rash and abnormal liver function&#xD;
      tests are observed. A better quality of life will probably be the beneficial effect of long&#xD;
      term treatment with AZT. This will be achieved by a reduction in respiratory and&#xD;
      non-respiratory symptoms and number of exacerbations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Does prolonged antibiotic treatment with AZM reduce the number of bacterial exacerbations in patients with bronchiectasis?</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Does treatment with AZM increase lung function parameters (Δ FEV1, Δ FVC )?</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Is there any improvement in symptom score during treatment with AZM?</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>What is the effect of AZM on bacterial colonisation?</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does treatment with AZM reduce inflammatory parameters?</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does treatment with AZM change the quality of life?</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Is there any differences in adverse events between AZM and placebo treatment?</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Bronchiectasis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Azithromycin treatment 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin Tablet 250 mg daily</description>
    <arm_group_label>Azithromycin treatment 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet 1 daily</description>
    <arm_group_label>Placebo 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 ≥ years&#xD;
&#xD;
          -  Bronchiectasis diagnosed by plain bronchography or high resolution computer&#xD;
             tomography.&#xD;
&#xD;
          -  Minimal 3 lower respiratory tract infections (LRTI) treated with oral/intravenous (IV)&#xD;
             antibiotics in the year preceding the study inclusion.&#xD;
&#xD;
          -  The presence of chronic respiratory symptoms such as cough, dyspnoea, expectoration of&#xD;
             sputum.&#xD;
&#xD;
          -  At least one positive sputum culture in the preceding year.&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous ( ≥ 4 weeks) prolonged macrolide therapy.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Allergy to macrolides.&#xD;
&#xD;
          -  Intolerance to macrolides.&#xD;
&#xD;
          -  Liver disease (alanine transaminase and/or aspartate transaminase levels 2 or more&#xD;
             times the upper limit of normal).&#xD;
&#xD;
          -  Use of antibiotics within 14 days of screening.&#xD;
&#xD;
          -  Use of oral or IV corticosteroids (≥ 30 mg prednisolone/daily) within 30 days of&#xD;
             screening.&#xD;
&#xD;
          -  Other research medication started 2 months prior to inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W.G. Boersma, MD,PHD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Center Alkmaar, dep. Pulmomary Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alkmaar Medical Center</name>
      <address>
        <city>Alkmaar</city>
        <state>N-H</state>
        <zip>1800AM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Lucas Andreas Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.L.C. Dekkerswald</name>
      <address>
        <city>Groesbeek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tergooi Ziekenhuizen</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viecuri MC</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 21, 2006</study_first_submitted>
  <study_first_submitted_qc>December 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical Center Alkmaar</investigator_affiliation>
    <investigator_full_name>W.G.Boersma</investigator_full_name>
    <investigator_title>Doctor, MD</investigator_title>
  </responsible_party>
  <keyword>Bronchiectasis</keyword>
  <keyword>Macrolide</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Antibiotic prophylaxis</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Lung function</keyword>
  <keyword>Sputum</keyword>
  <keyword>Bacterial colonization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

